NIH to Evaluate Iclaprim Activity against Listeria

    NEXT STORY
    The World Market for Orphan Drugs (2019-2023): Emergence of Combination Therapies & Novel Targets Spurs Market Growth
    PREV STORY
    Generex Biotechnology Announces Plans for NuGenerex Immuno-Oncology Spinout through a Targeted Acquisition of a Public Company and Planned Merger with Kiromic
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia

    author_avatar
    NASDAQ Market News

    Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388

    IL-27 is a key regulator of checkpoint protein expressionSRF388 believed to be the only ...

    author_avatar
    NASDAQ Market News

    PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101

    author_avatar
    NASDAQ Market News